Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Keryx Biopharmaceuticals is a biopharmaceutical company focused on the acquisition, development and commercialisation of novel pharmaceutical products for the treatment of life-threatening diseases, including cancer and diabetes. The company was incorporated in October 1998 (under the name Paramount Pharmaceuticals Inc, which was later changed to Lakaro Biopharmaceuticals Inc in November 1999, and finally to Keryx Biopharmaceuticals Inc in January 2000). The company commenced activities in November 1999, and since then has operated in one segment of operations, namely the development and commercialisation of clinical compounds and core technologies for the life sciences.